Medication augmentation after the failure of SSRIs for depression.

By Madhukar H. Trivedi, Maurizio Fava, S. Wisniewski, M. Thase, F. Quitkin, D. Warden, Louise Ritz, A. Nierenberg, B. Lebowitz, M. Biggs and 3 more. New England Journal of Medicine, 2006

990 citations recorded by the source corpus.

Subfields: Pharmacology, Psychiatry and Mental health

View Paper: https://www.semanticscholar.org/paper/54f4261935461447a3e8a87e953eb0903f312561

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

M. Schmulson
B. Birmaher
D. Brent
W. Bernet
O. Bukstein
H. Walter
R. S. Benson
G. Emslie

Citations in the corpus

What Is New in Rome IV (2017, background): “If necessary, an augumentation protocol, that is a combination of 2 or more treatments usually at lower dosages, that act at different receptor sites or areas of the brain may be used to enhance the therapeutic effect.(64) Narcotic bowel syndrome/opiate induced-gastrointestinal hyperalgesia is chara”
Practice parameter for the assessment and treatment of children and adolescents with depressive disorders. (2007, background): “In a landmark study of treatment-resistant depressed adults, after unsuccessful treatment with an SSRI, approximately one in four patients had a remission of symptoms after switching to another antidepressant (Rush et al., 2006 [rct], Trivedi et al., 2006 [rct]).”
Major depression. (2014, background): “Alternatively, 30% of subjects experienced remission with augmentation of the SSRI with bupropion or buspirone (although buspirone had higher dropout rates).(126) After failing to improve with the switch of medications, or augmentation, an additional 25% had remission of symptoms with augmentation w”
Antidepressant Efficacy of Ketamine in Treatment-Resistant Major Depression: A Two-Site Randomized Controlled Trial (2013, neutral): “Treatment-resistant major depression, defined as an insufficient response to at least two adequate antidepressant treatments, is associated with low rates of improvement with currently available antidepressant treatments (3, 4), and an intervention for refractory cases is thus an important unmet cli”